Kimura Disease of the Thigh Treated With Surgical Excision and Dupilumab

Ann Plast Surg. 2022 Mar 1;88(1s Suppl 1):S110-S113. doi: 10.1097/SAP.0000000000003106.

Abstract

Kimura disease (KD) is a rare, chronic inflammatory disorder presenting with solitary or multiple masses. Treatment options include surgical excision, corticosteroids, and radiotherapy; however, optimal therapy remains to be established. Moreover, efficacy of a humanized monoclonal antibody, dupilumab (Dupixent), requires to be demonstrated. Here, we present a 36-year-old male patient with an enlarging mass in the left medial thigh and chronic eczema over the abdomen and lower legs. Kimura disease was diagnosed after surgical excision. Postoperative treatment with dupilumab was applied with an initial dose of 600 mg followed by 300 mg every 2 weeks for 8 months. No recurrence of KD was observed in the 1-year follow-up. The eczematous lesions improved greatly. To our knowledge, this is the first report of using dupilumab for treating KD.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Kimura Disease*
  • Male
  • Thigh* / surgery
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab